A Phase I, Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of EMA401 Following Single Ascending Oral Dosing of EMA401.Na in Healthy Volunteers Administered Orally in the Fasted and Fed State.
Phase of Trial: Phase I
Latest Information Update: 22 Jun 2016
At a glance
- Drugs Olodanrigan (Primary)
- Indications Pain
- Focus Adverse reactions
- Sponsors Spinifex Pharmaceuticals
- 19 Jun 2009 Status changed from active, no longer recruiting to completed as reported by Australian New Zealand Clinical Trials Registry.
- 15 May 2009 New trial record